A Study of CM310 in Subjects With Moderate to Severe Asthma
- First Posted Date
- 2022-01-11
- Last Posted Date
- 2024-02-28
- Lead Sponsor
- Keymed Biosciences Co.Ltd
- Target Recruit Count
- 52
- Registration Number
- NCT05186909
- Locations
- 🇨🇳
China-Japan Friendship Hospital, Beijing, China
The Study of CM310 in Patients With Chronic Rhinosinusitis With Nasal Polyps
- First Posted Date
- 2021-11-23
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- Keymed Biosciences Co.Ltd
- Target Recruit Count
- 46
- Registration Number
- NCT05131464
- Locations
- 🇨🇳
Beijing Tong-Ren hospital, Beijing, China
🇨🇳Site 3, Chengdu, China
🇨🇳Site 2, Wuhan, China
Dose Escalation Trial of CM310 in Patients With Moderate-to-Severe Atopic Dermatitis (AD)
- First Posted Date
- 2021-05-20
- Last Posted Date
- 2021-06-04
- Lead Sponsor
- Keymed Biosciences Co.Ltd
- Target Recruit Count
- 39
- Registration Number
- NCT04893941
- Locations
- 🇨🇳
Hangzhou First People's Hospital, Hangzhou, Zhejiang, China
🇨🇳West China Hospital of Sichuan University, Chengdu, Sichuan, China
🇨🇳Peking University Third Hospital, Beijing, China
The Study of CM310 in Patients With Atopic Dermatitis
- First Posted Date
- 2021-05-19
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- Keymed Biosciences Co.Ltd
- Target Recruit Count
- 127
- Registration Number
- NCT04893707
- Locations
- 🇨🇳
Peking University People's hospital, Beijing, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath